OTC · Drug Manufacturers - Specialty & Generic

H. Lundbeck A/S (HLBBF) Stock

$6.60 +0.00% OTC: HLBBF Healthcare

H. Lundbeck A/S operates as an international biopharmaceutical entity, focusing its efforts on the entire lifecycle of pharmaceutical products—from initial research and development to manufacturing and global sales.

Valuation

MetricValue
Price$6.60
Market Cap$5.23B
P/E Ratio11.50
P/B Ratio1.66
P/S Ratio1.35
EPS (TTM)$0.57
52-Week High$7.55
52-Week Low$5.15
Dividend Yield2.73%

Financials & Margins

MetricValue
ROE14.81%
ROA7.07%
ROCE16.17%
Gross Margin78.95%
Operating Margin27.86%
Net Margin14.71%
Debt/Equity0.43
Current Ratio1.41

Annual Financials (USD)

Metric20212022202320242025
Revenue$16.3B$18.2B$19.9B$22.0B$24.3B
Operating Profit$2.0B$2.9B$3.2B$3.3B$6.3B
Net Profit$1.3B$1.9B$2.3B$3.1B$3.2B
EPS$1.33$1.93$2.31$3.17$3.21
Op Margin12.3%15.6%16.1%14.9%26.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$34.7B$37.5B$37.4B$57.0B$53.9B
Total Liabilities$16.4B$16.7B$15.4B$32.0B$29.0B
Cash$2.3B$3.4B$5.0B$4.7B$3.4B
Borrowings$5.3B$5.6B$4.2B$16.7B$11.7B

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$2.3B$3.5B$4.1B$3.3B$4.9B
Investing Cash Flow$-1.4B$-2.7B$-999.0M$-15.9B$-1.2B
Financing Cash Flow$-116.0M$-138.0M$-132.0M$-135.0M$488.0M
Net Cash Flow$-1.6B$1.3B$1.5B$-346.0M$-680.0M
Free Cash Flow$1.7B$2.7B$3.6B$2.8B$4.3B

Valuation & Return Ratios

MetricValue
PEG Ratio0.95
EV / EBITDA5.51
FCF Yield12.68%
Quick Ratio0.90
Interest Coverage11.75
Return 1Y24.62%
Return 3Y46.38%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
DNPUFSumitomo Pharma Co., Ltd. $8.41 +0.00% 4.78 $3.77B 0.00%
GZPHFGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited $2.34 +0.00% 12.06 $6.20B 5.56%
HKMPFHikma Pharmaceuticals PLC $20.37 +0.00% 0.19 $4.29B 4.71%
HKMPYHikma Pharmaceuticals PLC $42.02 +1.93% 0.19 $4.40B 4.57%
LVZPFLivzon Pharmaceutical Group Inc. $5.22 +0.00% 13.77 $6.06B 4.02%

About H. Lundbeck A/S

H. Lundbeck A/S operates as an international biopharmaceutical entity, focusing its efforts on the entire lifecycle of pharmaceutical products—from initial research and development to manufacturing and global sales. The firm primarily specializes in therapeutic solutions for psychiatric and neurological disorders across Europe, North America, and other worldwide regions. Among its prominent offerings are Abilify Maintena and Rexulti/Rxulti, prescribed for schizophrenia; Brintellix/Trintellix and Rexulti/Rxulti for the management of depression; Vyepti for the prevention of migraine attacks; and Northera, used to treat symptomatic neurogenic orthostatic hypotension. Lundbeck's diverse product lineup further includes Azilect for Parkinson's disease, Cipralex/Lexapro for depression, Ebixa for Alzheimer's disease, Onfi for Lennox-Gastaut syndrome, Sabril for epilepsy, and Xenazine for chorea associated with Huntington's disease, among others. The company's pharmaceuticals are primarily distributed to pharmaceutical wholesalers, retail pharmacies, and healthcare facilities like hospitals. Demonstrating a commitment to innovation and evidence-based medicine, Lundbeck has forged strategic alliances, including an agreement with Verantos to gather real-world evidence supporting migraine therapies, and a partnership with Rgenta Therapeutics, Inc. Founded in 1915, H. Lundbeck A/S maintains its corporate headquarters in Valby, Denmark.

H. Lundbeck A/S is headquartered in DK.

H. Lundbeck A/S (HLBBF) stock trades at $6.60 with a market capitalization of $5.23B. The stock is valued at a price-to-earnings (P/E) ratio of 11.50, price-to-book of 1.66, price-to-sales of 1.35. Over the past 52 weeks the stock has ranged between $5.15 and $7.55, and currently trades 12.6% below its 52-week high. It pays a dividend yielding 2.73%.

On profitability, H. Lundbeck A/S generates a return on equity (ROE) of 14.81%, above the typical market average, return on capital employed of 16.17%, an operating margin of 27.86%, a net profit margin of 14.71%.

Official website: www.lundbeck.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides